---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-118699"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:16:57.206528+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio: Phase 2 XPro1595 neuroimaging slows neurodegeneration in high-inflammation AD; MSC therapy review published

## Summary
- New PerpPD+ MRI imaging from Phase 2 MINDFuL trial shows trend toward slowed cortical disarray progression in early AD patients with high neuroinflammation (ADi).
- Data presented at CTAD conference; reinforces prior directional improvements on cognitive, biomarker, and neuropsychiatric endpoints.
- Additional MRI analyses from MINDFuL trial expected in 2026 to assess gray- and white-matter integrity.
- INmune Bio publishes peer-reviewed article on MSC therapies, including CORDStrom platform; BLA/MAA filing for RDEB expected in 2026.

## SEC filing metadata
- accession: 0001213900-25-118699
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025118699/0001213900-25-118699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025118699/ea0268534-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-118699
- JSON: https://secwatch.observer/filing/0001213900-25-118699.json
- Plain text: https://secwatch.observer/filing/0001213900-25-118699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.